Chinmay Jani, MD

Chinmay Jani, MD, of the University of Miami Sylvester Comprehensive Cancer Center, closes the discussion with Rajwanth R. Veluswamy, MD, MSCR, of the Perlmutter Cancer Center at NYU Langone Health, by naming the emerging data he is watching most closely in KRAS-mutated non-small cell lung cancer (NSCLC).

Rajwanth R. Veluswamy, MD, MSCR, and Chinmay Jani, MD, of the Perlmutter Cancer Center at NYU Langone Health and the University of Miami Sylvester Comprehensive Cancer Center, share their key takeaways on managing KRAS G12C-mutated non-small cell lung cancer.

Rajwanth R. Veluswamy, MD, MSCR, and Chinmay Jani, MD, of the Perlmutter Cancer Center at NYU Langone Health and the University of Miami Sylvester Comprehensive Cancer Center, discuss next-generation KRAS inhibitors in non-small cell lung cancer (NSCLC).

Rajwanth R. Veluswamy, MD, MSCR, and Chinmay Jani, MD, of the Perlmutter Cancer Center at NYU Langone Health and the University of Miami Sylvester Comprehensive Cancer Center, compare the tolerability of sotorasib and adagrasib in KRAS G12C-mutated non-small cell lung cancer.

Rajwanth R. Veluswamy, MD, MSCR, and Chinmay Jani, MD, of the Perlmutter Cancer Center at NYU Langone Health and the University of Miami Sylvester Comprehensive Cancer Center, discuss emerging KRAS G12C-directed agents in development for non-small cell lung cancer.

Rajwanth R. Veluswamy, MD, MSCR, and Chinmay Jani, MD, of the Perlmutter Cancer Center at NYU Langone Health and the University of Miami Sylvester Comprehensive Cancer Center, discuss second-line sequencing with sotorasib and adagrasib in KRAS G12C-mutated non-small cell lung cancer.

Rajwanth R. Veluswamy, MD, MSCR, of the Perlmutter Cancer Center at NYU Langone Health, and Chinmay Jani, MD, of the University of Miami Sylvester Comprehensive Cancer Center, review first-line immunotherapy outcomes in KRAS G12C-mutated non-small cell lung cancer.

Learn when to order tissue, liquid, and RNA testing to find KRAS G12C in lung adenocarcinoma and start treatment fast despite delayed results.

Learn when to order tissue, liquid, and RNA testing to find KRAS G12C in lung adenocarcinoma and start treatment fast despite delayed results.

In this episode of the Moonlight Shift, Jonathan Lee, MD, and Chinmay Jani, MD, dive into the ins and outs of oncology fellowship and training.

Learn why paired tissue and liquid NGS at diagnosis and progression uncovers actionable NSCLC alterations, guiding trials and future monitoring.

Explore NSCLC precision oncology gaps: expand targets beyond EGFR, refine liquid biopsies and MRD, and fix incomplete NGS testing.

Decode MET-altered lung cancer: amplification, exon 14 skipping and co-mutations, plus evolving targeted therapies and tumor board insights.

How Trop2 and MTAP-loss reshape NSCLC therapy, with AI pathology refining ADC response prediction and guiding trial referrals.

Learn how clinicians tackle EGFR lung cancer resistance—using NGS, radiation, chemo, amivantamab, and ADCs to tailor next-line therapy.

Learn how STK11 and MTAP loss reshape NSCLC prognosis, immunotherapy response, and open doors to dual-checkpoint and PRMT5 inhibitor trials.

See how KRAS mutations, especially G12C, guide NSCLC treatment sequencing—from PD-L1 strategy to sotorasib/adagrasib and emerging trials.

Experts unpack NGS, ctDNA and protein testing to speed actionable biomarker detection and guide targeted therapy choices in advanced lung cancer.

Experts explain combining tissue NGS, ctDNA liquid biopsy and IHC to uncover actionable NSCLC biomarkers and guide first-line targeted therapy.

Discover why combining tissue NGS, ctDNA and IHC uncovers actionable NSCLC biomarkers, shaping first-line therapy, resistance, and new ADC options.

Chinmay Jani, MD, discusses the rate of inclusion of patient-reported outcome end points in clinical trials of patients with lung cancer.